Oct 25 2024 79 mins
Visit https://www.peervoice.com/QFE860 to view the entire programme with slides. After completing “Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences”, participants will be able to: Evaluate clinical trial and real-world data which informs current evidence-based decision-making and treatment intensification in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC); Differentiate between androgen receptor pathway inhibitors (ARPIs) utilised in mHSPC and nmCRPC based on their pharmacologic profiles and clinical evidence; and Develop contemporary treatment plans for mHSPC and nmCRPC through application of a shared clinical decision-making approach which integrates the characteristics and preferences of individual patients.